3.56Open3.56Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover673.24%IV6.38%PremiumJan 17, 2025Expiry Date3.53Intrinsic Value100Multiplier12DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.8747Delta0.3768Gamma0.13Leverage Ratio-0.0045Theta-0.0007Rho-0.12Eff Leverage0.0002Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet